Pseudomonas aeruginosa adalah salah satu bakteri Gram-negatif 
INTRODUCTION
Nosocomial pneumonia is a nosocomial infection or health care-associated infections (HAIs) which consist of ventilator associated pneumonia (VAP), hospital acquired pneumonia (HAP) dan healthcare-associated pneumonia (HCAP) (Kollef et al 2005 , Tumbarello et al 2013 . Nosocomial pneumonia is the second most noso-comial infection in United States, in relation to increase of morbidity, mortality and hospital costs. Nosocomial pneumonia in United States occured in 5-15 cases every 1000 hospitalized patients and 6-21 times higher in patients with mecanical ventilator (Fishman 2013) .
About 20% nosocomial cases in ICU caused by Pseudomonas aeruginosa (Gaynes and Edwards, 2005) . ExoU is one of the effector proteins in addition to ExoS, ExoT and ExoY of type III secretion system (TTSS) P. aeruginosa. The function of TTSS is to inject toxin directly to cytoplasm eukaryote cell by using translocation needle-like apparatus (Hauser 2009 , Sawa 2014 . Previous research in animal showed that exoenzyme U ( ExoU) has the most important role in lung epithelial damage in pneumonia pathogenesis (Le Berre et al 2011) .
ExoU is a cytotoxin which has a phospholipase A2 activity that impaired phospholipid membrane then destruct the function of the cell (Diaz & Hauser 2010 , Hauser 2009 ). ExoU can interferes macrophages in phagocytosis and impaired epithelial barrier so that bacteria can disseminate into host (Hauser 2009 , Veesenmeyer et al 2010 .
Positivity genes encoding effector protein ExoU ( ExoU) varries to each P. aeruginosa isolates due to its strain and source of infection (Fleiszig et al 1997 , Feltman et al 2001 . The ExoU+ genes were detected about 25-30% from respiratory tract isolate and 40% from blood isolates (Feltman et al 2001 , Roy-Burman et al 2001 . Study in mice which are infected by ExoU expressed P. aeruginosa isolates until developed acute pneumonia showed a higher destruction of the lung tissues and mortality rate than infection caused by other effector proteins TTSS P. aeruginosa (Allewelt et al 2000; Shaver and Hauser, 2004) . It was supported by clinical study that P. aeruginosa strain with ExoU expression related to worse outcome and disease severity (El-Solh et al 2008; Hsu et al 2005; RoyBurman et al 2001) .
P. aeruginosa is one of Gram-negative bacteria that can be easily resistant to various antibiotics. As a group of fluoroquinolone with has potent antipseudomonas activity, ciprofloxacin has the highest resistancy rate to P. aeruginosa among Gram-negative bacteria (Gaynes et al 2005; Neuhauser et al 2003) . The prevalence of fluoroquinolone resistant (FQ-R) is increasing occured three times higher in P. aeruginosa isolates for the last three decades due to its overuse in therapy of community acquired pneumonia (CAP), urinary tract infection (UTI) and soft tissue and skin infection (SSI) (Neuhauser et al 2003) . The global epidemiology data showed that 18.4% of P. aeruginosa isolate from respiratory tract is resistant to ciprofloxacin (Dalhoff, 2012) . In case control study was known that FQ-R phenotype P. aeruginosa strains have worse clinical manifestation and three times higher mortality rate than fluoroquinolone sensitive (FQ-S) strain (Hsu et al 2005) . This study aimed to determine the positivity of ExoU gene TTSS P. aeruginosa and fluoroquinolone resistance in clinical isolates from sputum of pneumonia nosocomial VAP HAP HCAP patients in Sanglah Hospital, Bali.
MATERIALS AND METHODS

Baterial strains
A number of 53 isolates of P. aeruginosa were obtained from sputum of nosocomial pneumonia (VAP, HAP and HCAP) 
Bacterial re-growth and DNA extraction
Stock isolates were kept in TSB and glycerol 50% solutions, then were stored in -800C. P. aeruginosa bacteria were re-cultured on Nutrient agar medium, incubated at 35±20C for 18-24 hours. As many as 5-10 pure colonies were added into 100 µl TE solution pH 8.0 and mixed thoroughly. Briefly, the bacteria suspension were boiled at 100°C for 10 minutes, then the tube were chilled for 1-3 minutes. The suspension were centrifuged at 8000 g for 1 minute. The supernatan obtained was used as DNA template for PCR.
PCR for detection of Pseudomas aeruginosa specific gene and ExoU gene
PCR was performed to amplify the 16S rRNA of P. aeruginosa and ExoU gene. The oligonucleotide primer for 16S rRNA P. aeruginosa were, forward 5'-CAA AAC TAC TGA GCT AGA GTA CG-3 and reverse 5'-TAA GAT CTC AAG GAT CCC AAC GGC T-3' (Matsuda et al 2007) and oligonucleotide primer for ExoU were, forward 5'-CCG TTG TGG TGC CGT TGA AG -3' and reverse 5'-CCA GAT GTT CAC CGA CTC GC-3' (Ajayi et al 2003) . Mix PCR for PCR 16S rRNA P. aeruginosa consist of 12.5 µl Go Taq® Green Master Mix Promega, primers with each concentration 0.8 µM, 2 µl template DNA and ddH2O until final volume 25 µl. The PCR cycle was run as follows: initial denaturation at 95°C for 3 min; 35 cycles of 95°C for 1 min, 55°C for 1 min, 72°C for 90s; and a final extension step at 72°C for 7 min. Mix PCR for ExoU consist of 12.5 µl Go Taq® Green Master Mix Promega, forward and reverse primer each concentration 0.4 µM, 1 µl template DNA and ddH2O until final volume 25 µl. The PCR cycle was run as follows: initial denaturation at 95°C for 3 min; 36 cycles of 95°C for 15 s, 54°C for 15 s, 72°C for 1 min; and a final extension step at 72°C for 1 min. The amplicon was electrophoresed into 1,5% agarose gel, stained with 1 µl gel red at 50 volt for 60 min.
Fluoroquinolone resistance
The antimicrobial susceptibility testing (AST) of fluoroquinolone against P. aeruginosa were conducted by Vitek2 Compact system (bioMérieux, Inc., Marcyl'Etoile -France) with breakpoint of sensitive (MIC=1 µg), intermediate (1<MIC<4 µg) and resistant (MIC=4 µg). The intermediate and resistant were grouped into resistant cathegory (Patel et al 2015) .
RESULTS
Fifty-three isolates were detected phenotypically and genotipically as a P. aeruginosa bacterium. In this study phenotype detection were performed by automated Vitek2 compact system (bioMérieux, Inc., Marcyl'Etoile, France), while genotype detection by amplifying 16S rRNA P. aeruginosa gene (Fig. 1) .
Co-infection bacteria in nosocomial pneumonia caused by P. aeruginosa
There were two bacterial species identified from 15 isolates (15.3%) on culture media, that were decided as coinfection in nosocomial pneumonia. The most common bacteria that cause coinfection was Klebsiella pneumonia ssp pneumoniae (7/46%), followed by Acinetobacter baumanii (4/27%) and Escherichia coli (2/13%). Other bacteria that were identified as a cause of coinfection were Enterobacter aerogenes and Providencia rettgeri (1 isolate each/7%) (Fig. 2) .
Ciprofloxacin resistance of P. aeruginosa
Based on antimicrobial susceptibility testing to P. aeruginosa isolates from nosocomial pneumonia patients, 31 isolates (58.5 %) were sensitive, while 22 isolates (41.5%) were resistant to ciprofloxacin (table 1). The group with the highest proportion of Ciprofloxacin resistant were in VAP group (54.5%), whilst HCAP and HAP only accounted for 27.3% dan 18.2% (Table 1) . 
Detection of ExoU gene
Detection of ExoU gene as an encoding efector protein exoenzyme U TTSS P. aeruginosa used uniplex PCR (Fig. 3) . The proportion of ExoU gene on this study were 66.1% (5 isolates). Based on nosocomial pneumonia type, the highest proportion of ExoU gene was on VAP 57.1% (20 isolates), whereas the proportion in HAP and HCAP were 14.3% (5 isolates) and 28.6% (10 isolates), respectively.
DISCUSSION
Nosocomial pneumonia mostly caused by Gram-negative rods (65.9%) and P. aeruginosa is known as the most frequent bacterial causative agent (18.1%) (Gaynes & Edwards, 2005) . Nosocomial pneumonia caused by P. aeruginosa correlates with increasing of morbidity, length of hospital stay, cost and mortality rate (Vincent et al 2006) . As the most important effector protein in pneumonia pathogenesis, ExoU has a phospholipase A2 (PLA2) activity that impaired phagocytosis and cause epithelial damage (Hauser 2009 , Veesenmeyer et al 2010 . The PLA2 produced by ExoU similar to mammalian PLA2 enzyme that has cytotoxic activity to eukaryote cells (Hurley & McCormick, 2008) . PLA2 activity can also impaired surfactan's function in the lungs due to phos-pholipid hydrolysis (Kirschnek & Gulbins 2006) .
ExoU is one of effector protein of TTSS P. aeruginosa that really contribute to epithelial damage of lung in pneumonia (Le Berre et al 2011) . Infections caused by P. aeruginosa that express ExoU strongly related to severity of pneumonia with its higher complication and mortality rate (Sato & Frank, 2004) . On this study, proportion of ExoU gene encoding ExoU was 66,1%. Wong-Beringer et al (2008) and Roy-Burman et al (2001) showed that proportion of ExoU gene from sputum specimen between 23-30%. Feltman et al (2001) showed that proportion of ExoU gene from lower respiratory tract specimens was 17.5%. Lomholt et al (2001) showed that proportion of ExoU from all specimens and sputum were 34% and 4%, respectively. A higher proportion of ExoU showed by Cho et al (2014) , 56.8%.
The high proportion of ExoU gene due to its clonality of isolates and pathogen (Roy-Burman et al 2001; Zhu et al 2006) . The high proportion of ExoU+ gene can be obtained by horizontal gene transfer (HGT) mechanism that indicate not only highly virulence P. aeruginosa strain but also its ability to colonize and survive in environment (Wolfgang et al 2003) .
ExoU were expressed during acute phase of infection and contribute to severe pneumonia due to phagocytosis impairment. Thus can lead P. aeruginosa persist in lungs caused local immunosuppression subsequently facilitate coinfection by other lower pathogenicity bacteria (Diaz et al 2008; Sawa et al 2014) . On this study showed patients with coinfection and Klebsiella pneumonia ssp pneumoniae as the most common bacteria (7 isolates/46%). A study from Tumbarello et al (2013) found that Acinetobacter baumanii as the most causes of coinfection (7 isolat/6.4%). Based on previous studies, pneumonia caused by P. aeruginosa that expressed ExoU not only induce serious infection but also polimicrobial infection (Diaz et al 2008; Sawa et al 2014) .
Resistance of P. aeruginosa to ciprofloxacin tend to increase in few decades due to over prescribe for empirical therapy (Dalhoff 2012 , Neuhauser et al 2003 .
On this study ciprofloxacin resistant was found 41.5%. El-Solh et al (2012) showed that ciprofloxacin resistant in P. aeruginosa respiratory isolates was 59%. The lower proportion of ciprofloxacin resistant from lower respiratory isolates was found by Zhanel et al (2010) accounted for 18.4%. From several clinical studies showed that patients with P. aeruginosa infections tend to have worse clinical outcome if the isolates express ExoU and has fluoroquinolone resistant phenotype (Hsu et al 2005; Roy-Burman et al 2001) .
On this study, ciprofloxacin resistant isolates with MDRO phenotype were very high if compared to Non-MDRO (81.8% vs 18.2%). A retrospective multicenter study by Micek et al (2015) indicate that nosocomial pneumonia prevalence caused by MDRO phenotype P. aeruginosa was 30.5%. Based on that finding, the most common risk factors impact to MDRO pnenotype are history of antibiotic in 30 days, chronic obstructive pulmonary disease and diabetes mellitus. MDRO phenotype were more predominant in ICU patients (44.4%) than Non-ICU patients (20%) (Tumbarello et al 2013) . Hsu et al (2005) showed that MDRO phenotype has 12.6 times higher fluoroquinolone resistant. Pneumonia caused by MDRO phenoytype P. aeruginosa altered failure therapy and impact to high mortality rate (Sawa 2014) . Fluoroquinolone resistant strain P. aeruginosa conferred cross resitance to other antipseudomonas groups that was underlying MDRO (Neuhauser et al 2003) . Efflux pump overexpression (EPO) is a mechanism involved in MDRO phenotype P. aeruginosa. The occurance of EPO due to mutation in genes nalB, nfxB dan nfxC. Mutation of those genes then accomodate various substrate that structural unrelated from cytoplasma to periplasma space of bacteria subsequently conferred resistance to various class of antibiotics (Hancock 1998 , Poole 2000 .
Fluoroquinolone resistant can be occured by over exposure of antibiotic that leads to chromosome recombination which encode resistance and virulence genes (Fitzgerald et al 2001) . The mutation of gyrA gene in resistance mechanism in fluoroquinolone conferred to DNA supercoiling that lead to bacteria virulence gene expression , Dorman 1990 ). Mutation in gyrA gene causes impairment of negative supercoiling DNA that lead the resistance of fluoroquinolone then induce expression of gene encoding effector protein TTSS P. aeruginosa (Wong-Beringer, 2008) . Tran et al (2011) showed that gyrA mutation in codon Ile83Thr and parcC mutation in codon Leu87Ser correlate with expression of gene encoding TTSS P. aeruginosa.
To date, the precise mechanism how gene encoding effector protein TTSS P. aeruginosa being expressed due to gyrA mutation is not well documented. Generally regulation to expression genes encoding effector protein consist of intrinsic and extrinsic regulation. ExsA has an important role in central regulator in intrinsic regulation and Vfr (Virulence factor regulator) as an extrinsic regulation (Diaz, King and Yahr, 2011) . Chen et al (2016) showed that an enzyme called oligoribonuclease (Orn) involved in TTSS P. aeruginosa expression by contact dependent between bacteria and host cell. That enzyme was conserved in bacteria which has a 3'-5' exonuclease activity that break 2-5-nt RNA (nanoRNA) to mononucleotide. If Orn decreases, there will increase of nanoRNA and cyclic-di-GMP (C-di-GMP) that can decrease expression TTSS P. aeruginosa (Chen et al 2016 , Chen et al 2017 . C-di-GMP altered the amount of cAMP levels that induce expression of TTSS genes by cAMP reseptor protein Vfr (Chen et al 2016) .
If DNA damage occured due to gyrA mutation will lead to SOS response (Wu & Jin 2005) . SOS response is a response occur to cell that encountered DNA damage or impaired DNA replication subsequently impact to cell cleavage and increase of DNA repair and mutagenesis (Little & Mount 1982) . Chen and colleagues (2017) showed that in Orn mutant there would be up-regulation to genes involved in SOS response that initiate DNA damage. Based on that study can be assumed that role of Orn in DNA damage due to gyrA mutation in fluoro-quinolone resistant isolate will induce expression of TTSS P. aeruginosa genes.
CONCLUSION
In nosocomial pneumonia (VAP, HAP and HCAP), the positivity of ExoU+ gene were more likely found in Ciprofloxacin resistant group than in Ciprofloxacin sensitive group. Based on nosocomial type, the highest proportion of isolates genotypically ExoU+ and phenotypically Ciprofloxacin resistant were found in VAP group accounted for 57.1% and 54.5%, respectively. There was significant correlation between ciprofloxacin resistance and ExoU gene (p=0.001).
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